Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 4, 2012, Pages 518-523

  van Rhijn, Bas W G ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Bladder; Cancer; FGFR3; Gene classifier; Grade; Immuno histochemistry; Molecular grade; Progression; Recurrence; Reproducibility; Stage

Indexed keywords

KI 67 ANTIGEN; MOLECULAR MARKER;

CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; NON MUSCLE INVASIVE BLADDER CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REPRODUCIBILITY; REVIEW;

HUMANS; MUTATION; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SENSITIVITY AND SPECIFICITY; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84863006174     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.04.002     Document Type: Review

References (44)

1. Ferlay J., Bray F., Pisani P., et al. Cancer incidence, mortality and prevalence worldwide. IARC CancerBase, version 1.0; 2002 No. 5 2004, IARCPress, Lyon, Accessed September 15, 2010. http://www-dep.iarc.fr.
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 2008, 2008:71-96.
3. Colombel M., Soloway M., Akaza H., et al. Epidemiology, staging, grading, and risk stratification of bladder cancer. Eur Urol Suppl 2008, 7:618-626.
4. Wu X., Ros M.M., Gu J., et al. Epidemiology and genetic susceptibility to bladder cancer. BJU Int 2008, 102:1207-1215.
5. Babjuk M., Oosterlinck W., Sylvester R., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008, 54:303-314.
6. Kirkali Z., Chan T., Manoharan M., et al. Bladder cancer: Epidemiology, staging and grading, and diagnosis. Urology 2005, 66(Suppl 6A):4-34.
7. Kiemeney L.A., Witjes J.A., Verbeek A.L., et al. The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group. Br J Cancer 1993, 67:806-812.
8. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49:466-477.
9. Hall M.C., Chang S.S., Dalbagni G., et al. Guideline for the management of non-muscle-invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007, 178:2314-2330.
10. Botteman M.F., Pashos C.L., Redaelli A., et al. The health economics of bladder cancer. Pharmacoeconomics 2003, 21:1315-1330.
11. Riley G.F., Potosky A.L., Lubitz J.D., et al. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995, 33:828-841.
12. Van Rhijn B.W.G., Burger M., Lotan Y., et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: From epidemiology to treatment strategy. Eur Urol 2009, 56:430-442.
13. Kaufman D.S., Shipley W.U., Feldman A.S. Bladder cancer. Lancet 2009, 374:239-249.
14. van Rhijn B.W.G., van Leenders G.J.L.H., Ooms E.C.M., et al. The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading. Eur Urol 2010, 57:1052-1057.
15. Van der Meijden A., Sylvester R., Collette L., et al. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: A combined analysis of 5 European Organization for Research and Treatment of Cancer trials. J Urol 2000, 164:1533-1537.
16. Zieger K., Wolf H., Olsen P.R., et al. Long-term follow-up of noninvasive bladder tumours (stage Ta): Recurrence and progression. BJU Int 2000, 85:824-828.
17. Millán-Rodríguez F., Chéchile-Toniolo G., Salvador-Bayarri J., et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000, 163:73-78.
18. Millán-Rodríguez F., Chéchile-Toniolo G., Salvador-Bayarri J., et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000, 164:680-684.
19. Sylvester R.J. Natural history, Recurrence and progression in superficial bladder cancer. TSW. Urology 2006, 1:15-23.
20. Kurth K.H., Sylvester R.J. Prognostic factors in non-muscle-invasive bladder tumors. I: Clinical prognostic factors: A review of the experience of the EORTC Genito-urinary group. II: Biologic prognostic markers. Eur Urol 2007, 6(Suppl):789-799.
21. Fernandez-Gomez J., Solsona E., Unda M., et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: Multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008, 53:992-1001.
22. Stein J.P., Grossfeld G.D., Ginsberg D.A., et al. Prognostic markers in bladder cancer: A contemporary review of the literature. J Urol 1998, 160:645-659.
23. Duggan B.J., McKnight J.J., Williamson K.E., et al. The need to embrace molecular profiling of tumor cells in prostate and bladder cancer. Clin Cancer Res 2003, 9:1240-1247.
24. Knowles M.A. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese. Carcinogenesis 2006, 27:361-373.
25. van Rhijn B.W.G., Vis A.N., van der Kwast T.H., et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003, 21:1912-1921.
26. Burger M., van der Aa M.N., van Oers J.M., et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: A prospective study. Eur Urol 2008, 54:835-843.
27. Shariat S.F., Ashfaq R., Sagalowsky A.I., et al. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 2007, 177:481-487.
28. Moonen P.M., van Balken-Ory B., Kiemeney L.A., et al. Prognostic value of P53 for high risk superficial bladder cancer with long-term follow-up. J Urol 2007, 177:80-83.
29. Schultz I.J., Wester K., Straatman H., et al. Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma. Eur Urol 2007, 51:416-422.
30. Burger M., Denzinger S., Hartmann A., et al. Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade. Br J Cancer 2007, 96:1711-1715.
31. Dyrskjøt L., Thykjaer T., Kruhøffer M., et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003, 33:90-96.
32. Dyrskjøt L., Zieger K., Real F.X., et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: A multicenter validation study. Clin Cancer Res 2007, 13:3545-3551.
33. Kamat A.M., Gee J.R., Dinney C.P., et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 2006, 175:881-885.
34. Kunju L.P., You L., Zhang Y., et al. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens. J Urol 2008, 180:1928-1932.
35. van Rhijn B.W.G., Zuiverloon T.C.M., Vis A.N., et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol 2010, 58:433-441.
36. Spruck C.H., Ohneseit P.F., Gonzalez-Zulueta M., et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994, 54:784-788.
37. Karam J.A., Shariat S.F., Hsieh J.T., et al. Genomics: A preview of genomic medicine. BJU Int 2008, 102:1221-1227.
38. Schmitz-Dräger B.J., Goebell P.J., Ebert T., et al. p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?. Eur Urol 2000, 38:691-699.
39. Hernández S., López-Knowles E., Lloreta J., et al. Prospective study of FGFR3 mutations as a prognostic factor in non-muscle-invasive urothelial bladder carcinomas. J Clin Oncol 2006, 24:3664-3671.
40. Shariat S.F., Zlotta A.R., Ashfaq R., et al. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol 2007, 20:445-459.
41. van Rhijn B.W.G., van der Kwast T.H., Kakiashvili D.M., et al. Pathological stage review is indicated in primary pT1 bladder cancer. BJU Int 2010, 106:206-211.
42. McShane L.M., Aamodt R., Cordon-Cardo C., et al. Reproducibility of p53 immunohistochemistry in bladder tumors. Clin Cancer Res 2000, 6:1854-1864.
43. Wild P.J., Herr A., Wissmann C., et al. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res 2005, 11:4415-4429.
44. Lindgren D., Liedberg G., Andersson A., et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 2006, 25:2685-2696.